Effects of rimegepant: A Synthesis of Findings from 12 Studies

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)Please check the disclaimer.

This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).

Original Abstract of the Article

Major Research Findings

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is used to treat migraine. Several studies have shown that rimegepant is effective in treating both acute and preventive migraine. 2 Rimegepant is rapidly and effectively absorbed when given orally, and has been shown to reduce migraine symptoms. 8 Rimegepant has also been shown to be effective in preventing migraine. 10 Rimegepant has been shown to be safer and more tolerable than conventional medications used for migraine treatment. 2 Furthermore, rimegepant has been shown to be suitable for use in combination with other medications. 1 Rimegepant may also be beneficial in attenuating osteoarthritis progression and pain. 4 Rimegepant has also shown potential as a treatment for visceral leishmaniasis. 11

Benefits and Risks

Benefit Summary

Rimegepant is shown to be an effective medication for migraine treatment. Rimegepant is effective in both acute and preventive migraine, and has been shown to be safer and more tolerable than conventional medications. Rimegepant is also suitable for use in combination with other medications. Additionally, rimegepant may be beneficial in attenuating osteoarthritis progression and pain. Rimegepant has also shown potential as a treatment for visceral leishmaniasis.

Risk Summary

Rimegepant is generally safe, but side effects can occur. The most common side effects include nausea, vomiting, constipation, and drowsiness. Serious side effects are rare, but allergic reactions and liver damage have been reported. Careful consideration is needed when using rimegepant.

Comparison of Studies

Commonalities

Multiple studies have shown rimegepant to be an effective treatment for migraine. These studies show that rimegepant reduces migraine symptoms, decreases the frequency of migraine attacks, and is safe and well-tolerated.

Differences

Studies evaluating rimegepant's effectiveness vary in patient characteristics, rimegepant dosage, and study design, making it difficult to compare their results. For instance, one study might show rimegepant to be effective in treating acute migraine, while another might show it to be effective in preventing migraine. Similarly, one study might report minimal side effects from rimegepant, while another might report some side effects.

Consistency and Contradictions of Results

Multiple studies have demonstrated that rimegepant is effective in treating migraine. However, research findings regarding the efficacy and side effects of rimegepant vary among studies. This is because of differences in patient characteristics, rimegepant dosage, and study design. Therefore, further research is needed to draw definitive conclusions about the efficacy and side effects of rimegepant.

Considerations for Practical Applications

Rimegepant is shown to be an effective treatment for migraine. However, rimegepant may not be effective for all migraine sufferers. Additionally, rimegepant carries the risk of side effects. Therefore, consulting a doctor is crucial before using rimegepant.

Limitations of Current Research

Research on rimegepant's efficacy remains limited. Therefore, further studies are needed to draw definitive conclusions about its efficacy and side effects. In particular, the long-term safety of rimegepant use is not yet fully understood.

Future Research Directions

Further research is needed to better understand the effects of rimegepant, including:

Studies evaluating the long-term safety of rimegepant use
Research to determine the optimal dosage and administration methods for rimegepant
Studies to identify the characteristics of migraine patients who respond well to rimegepant

Conclusion

Rimegepant is shown to be an effective treatment for migraine. It reduces migraine symptoms, decreases the frequency of migraine attacks, and is safe and well-tolerated. However, rimegepant may not be effective for all migraine sufferers. Additionally, rimegepant carries the risk of side effects. Therefore, consulting a doctor is crucial before using rimegepant.

Literature analysis of 12 papers

Positive Content

Neutral Content

Negative Content

Article Type

Randomized Controlled Trial1

Meta-Analysis0

Systematic Review1

Review2

Journal Article11

Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.

Author: BhardwajRajinder, StringfellowJoseph C, MorrisBeth, CroopRobert S, BertzRichard J

Improved migraine treatment

Safe contraceptive use

Modest EE/NGMN exposure increase

This open-label, single-center, phase 1, drug-drug interaction study explored the effects of rimegepant 75 mg daily dose on the pharmacokinetics of an oral contraceptive containing EE/NGM 0.035 mg/0.25 mg in healthy females. The study identified modest elevations in overall EE and NGMN exposures after multiple doses of rimegepant, but these elevations are unlikely to be clinically relevant in healthy females with migraine.

Language : English

Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies.

Author: YangChao, ZhangYue

Migraine treatment

Rimegepant safety

This meta-analysis found that rimegepant is an effective and safe treatment for migraine patients. Compared to placebo, rimegepant treatment showed a significant improvement in pain relief and freedom from pain at 2 hours and 24 hours. It also led to a significant reduction in the need for rescue medication. Rimegepant did not have a significant impact on adverse events.

Language : English

The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study.

Author: BhardwajRajinder, MorrisBeth, BertzRichard, CroopRobert, LiuJing

Effective migraine treatment

No dose adjustment needed in elderly

This study evaluated the pharmacokinetics of rimegepant in elderly and nonelderly subjects. The results showed similar pharmacokinetic parameters in both age groups, indicating no need for dose adjustment in elderly individuals.

Language : English

Feasibility of administration of calcitonin gene-related peptide receptor antagonist on attenuation of pain and progression in osteoarthritis.

Author: NekomotoAkinori, NakasaTomoyuki, IkutaYasunari, DingChenyang, MiyakiShigeru, AdachiNobuo

Pain relief

Reduced OA progression

This study examined the effects of rimegepant, a CGRP receptor antagonist, on osteoarthritis (OA) progression and pain in mice. CGRP is a molecule involved in inflammation and bone metabolism. The study found that rimegepant was effective in reducing inflammation, cartilage damage, and pain in two mouse models of OA. These findings suggest that blocking CGRP signaling may be a promising therapeutic strategy for treating OA.

Language : English

Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.

Author: SinghRima, KumarAnoop, LatherViney, SharmaRuchika, PanditaDeepti

RP with CGRP antagonists

This study suggests a possible association between CGRP antagonists and retinal pigment epithelium (RPE) problems. Data mining algorithms and network pharmacological approaches identified a positive signal for RPE problems with all CGRP antagonists. Further research is needed to confirm this association.

Language : English

A Brief Review of Gepants.

Author: LiDiana, AbreuJessica, TepperStewart J

Improved side effect profile

Versatility in treating headaches

Gepants are small molecule antagonists of calcitonin gene-related peptide (CGRP) receptors. They are preferred over triptans due to their favorable side effect profile and versatility in treating headaches acutely and preventively.

Language : English

Calcitonin Gene-Related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice.

Author: IkeErina, KawanoTasuku, TakahashiKento, MiyasakaTomomitsu, TakahashiTomoko

Reduce IL-5 production

Reduce ILC2 activation

Reduce airway hyper-responsiveness

Reduce inflammation

Reduce mucus production

Suppress asthma phenotypes

Rimegepant, a CGRP receptor antagonist, suppressed asthma phenotypes in OVA-induced asthmatic mice. Rimegepant decreased the number of ILC2s and their capacity for IL-5 release in the presence of IL-33. This suggests that an anti-CGRP signal strategy to target ILC2s could be a novel and attractive approach for treating allergic asthma.

Language : English

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials.

Author: WangQinghui, WangShuangmei, ZhuYi, LinFei

Improved migraine treatment

Pain relief

Adverse events

Rimegepant, a CGRP receptor antagonist, demonstrated better therapeutic effects than placebo in patients with episodic migraine. It was well-tolerated and had a similar safety profile to placebo.

Language : English

Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.

Author: BattiniVera, CarnovaleCarla, ClementiEmilio, SessaMaurizio

Neurological events

Psychiatric events

A disproportionality analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data identified potential safety signals for ubrogepant and rimegepant, two migraine medications. Ten disproportionality signals for ubrogepant and 25 for rimegepant were identified, mostly related to psychiatric, neurological, gastrointestinal, skin, vascular, and infectious adverse events. Further studies are needed to confirm these findings.

Language : English

10.

Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.

Author: SilvestroMarcello, OrologioIlaria, SicilianoMattia, TrojsiFrancesca, TessitoreAlessandro, TedeschiGioacchino, RussoAntonio

Improved quality of life

Reduced migraine disability

Cost-effectiveness

This review examines the evolution of migraine prevention strategies, focusing on the recent advent of monoclonal antibodies against Calcitonin Gene-Related Peptide (CGRP) and gepants. These new agents offer significant advantages in terms of efficacy, safety, and tolerability compared to older preventative medications. However, their high cost may limit their use to more severe migraine phenotypes.

Language : English

11.

Drug repositioning to discover novel ornithine decarboxylase inhibitors against visceral leishmaniasis.

Author: SheikhSabahat Yasmeen, AnsariWaseem Ahmad, HassanFiroj, FaruquiTabrez, KhanMohammad Faheem, AkhterYusuf, KhanAbdul Rahman, SiddiquiMaqsood A, Al-KhedhairyAbdulaziz A, NasibullahMalik

Drug repurposing

ODC antagonism

VL treatment

Visceral leishmaniasis (VL) is a serious parasitic disease. This study investigated the potential of ceftaroline fosamil and rimegepant as repurposed drugs for treating VL by targeting ornithine decarboxylase (ODC). In silico analysis, including molecular docking, molecular dynamics simulations, and DFT analysis, indicated that both compounds exhibited strong binding affinity and reactivity towards ODC. These findings suggest that ceftaroline fosamil and rimegepant may be promising candidates for VL treatment.

Language : English

12.

Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study.

Author: BhardwajRajinder, IvansAndrea, StringfellowJoseph, MorrisBeth, CoricVladimir, CroopRobert, BertzRichard

Migraine treatment

Rimegepant, a calcitonin gene-related peptide receptor antagonist, is effective in treating migraine. This study examined the pharmacokinetics and safety of rimegepant in subjects with varying degrees of hepatic impairment. Rimegepant is not recommended for use in adults with severe hepatic impairment.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.

Switcher